Skip to main content

Advertisement

Table 1 Clinical characteristics of the 85 nasopharynx cancer patients from NCC0901 who were recruited to the exploratory biomarker study

From: Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC

Clinical parameters Frequency (%)
Median time interval between last RT and sample collection, y (IQR) 5.5 (4.2–7.0)
Range 3.3–11.4
Median age at diagnosis, y (IQR) 48 (41.5, 53.8)
Range 21.2–67.0
Median age at collection, y (IQR) 55 (48.4, 60.0)
Range 25.2–74.5
Age (at time of collection)
  ≤ 55 42 (49.4)
  > 55 43 (50.6)
Gender
 Male 64 (75.3)
 Female 21 (24.7)
T-category
 T0–2 43 (50.6)
 T3–4 42 (49.4)
N-category
 N0–1 10 (11.8)
 N2–3 75 (88.2)
TNM stage
 III 57 (67.1)
 IVA/B 28 (32.9)
cfEBV DNA copy number status
 Positive 40 (47.1)
 Negative 18 (21.2)
Not tested 27 (31.8)
Treatment assigned
 Induction GCP + CRT 44 (51.8)
 CRT only 41 (48.2)
  1. Abbreviations: EBV Epstein-barr virus, GCP gemcitabine, carboplatin, paclitaxel, CRT chemo-radiotherapy